2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MPN, CML, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

5483 Myeloproliferative neoplasms induce compartment-specific remodeling across the skull-brain axis

Tesa Klenovšek, MS, Stijn Fuchs2, Hector Tejeda Mora, PhD3, Gerjanne Vroeg in de wei4, Iris Jade Bakker, MS5, Jessica Pritchard6, Stephani Schmitz7, Tobias Seibel8, Hanbing Gao9, Salim Atakhanov10, Eric Bindels11, Alexandru Florea12, Nicolaus Kröger13, Felix Mottaghy14, Carolin Victoria Schneider, MD15, Rebekka Schneider, MD, PhD16, Helene Gleitz, PhD17
1 Erasmus MC, Rotterdam, Netherlands
2 Erasmus MC, Rotterdam, Netherlands, Oncode Institute, Rotterdam, Netherlands
3 Erasmus MC, Rotterdam, Netherlands
4 Erasmus MC, Rotterdam, Netherlands
5 Erasmus MC, Rotterdam, Netherlands
6 Erasmus MC, Rotterdam, Netherlands, Oncode Institute, Rotterdam, Netherlands, University Hospital RWTH Aachen, Aachen, Germany
7 Erasmus MC, Rotterdam, Netherlands, Oncode Institute, Rotterdam, Netherlands
8 University Hospital RWTH Aachen, Aachen, Germany
9 University Hospital RWTH Aachen, Aachen, Germany
10 University Hospital RWTH Aachen, Aachen, Germany
11 Erasmus MC, Rotterdam, Netherlands
12 Maastricht University Medical Center+, Maastricht, Netherlands, Maastricht University, Maastricht, Netherlands, University Hospital RWTH Aachen, Aachen, Germany
13 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
14 Maastricht University Medical Center+, Maastricht, Netherlands, Maastricht University, Maastricht, Netherlands, University Hospital RWTH Aachen, Aachen, Germany
15 University Hospital RWTH Aachen, Aachen, Germany
16 Erasmus MC, Rotterdam, Netherlands, Oncode Institute, Rotterdam, Netherlands, University Hospital RWTH Aachen, Aachen, Germany
17 Erasmus MC, Rotterdam, Netherlands, Oncode Institute, Rotterdam, Netherlands, University Hospital RWTH Aachen, Aachen, Germany

Myeloproliferative neoplasms (MPNs) are chronic myeloid malignancies associated with a substantial symptom burden that severely impacts patients' quality of life. Neurological manifestations, including fatigue, headaches, cognitive impairment, and sleep disturbances, are commonly attributed to systemic inflammation and microvascular dysfunction, yet current therapies provide limited symptomatic relief. Recent studies have identified the cranium as a distinct hematopoietic compartment that directly communicates with the meninges and contributes to brain-border immunity. While MPN-associated remodeling of the femoral BM and spleen is well established, the impact on cranial hematopoiesis and brain immune homeostasis remains unknown.

To characterize MPN-associated alterations across the skull-brain axis, we employed murine models of thrombopoietin overexpression, JAK2V617F, and MPLW515L-driven disease (n=5/group). To minimize irradiation-associated neurotoxicity, mice were conditioned using reduced-intensity busulfan prior to BM transplantation. Single-cell RNA sequencing (scRNA-seq), flow cytometry, and immunohistochemistry were performed to evaluate cranial BM, meninges, and brain. Human validation included cranial bone mineral density (BMD) and cerebral glucose metabolism assessment using 18F-FDG PET/CT imaging in patients with myelofibrosis (MF, n=7) and healthy controls (n=8), complemented by UK Biobank neuroimaging analysis.

Donor hematopoietic stem cells (HSCs) successfully engrafted cranial BM niches in control and MPN mice. MPNs induced marked expansion of cranial HSCs and progenitors, accompanied by a significant increase in granulocytic and monocytic lineages, and reduced lymphopoiesis. Notably, disease-driving CXCL4+ megakaryocytes (MKs) were markedly expanded within cranial BM niches. Unexpectedly, despite robust myeloid expansion, scRNA-seq analysis revealed downregulation of pro-inflammatory programs, characterized by reduced expression of IL-1β, IL-6, TNF-α, and S100A8/A9, while TGF-β- and PDGF-associated profibrotic pathways were activated across MKs, monocytes, and macrophages (Mφ). This remodeling was accompanied by expansion of activated α-SMA+ and FAP+ fibroblasts with enhanced extracellular matrix production and reticulin deposition, consistent with cranial myelofibrosis. In contrast to the osteosclerotic phenotype typically observed in long bones during MPN progression, cranial osteoblasts demonstrated impaired osteogenic transcriptional programs, whereas osteoclasts acquired enhanced bone-resorption signatures. Consistent with these findings, patients with MF exhibited significantly reduced cranial BMD compared to healthy controls, while femurs displayed osteosclerosis.

In contrast to the cranial BM niche, the adjacent dura mater underwent profound inflammatory remodeling. Myeloid accumulation was accompanied by increased expression of inflammatory cytokines (IL-1β, IL-6, and TNF-α), enhanced migratory and antigen-presentation programs, and activation of matrix-remodeling pathways, particularly within granulocytic populations. Meningeal perivascular fibroblasts acquired angiogenic and profibrotic transcriptional programs, while endothelial cells promoted adhesion, chemotaxis, and inflammation. In MPN mice, whole-mount imaging confirmed increased meningeal vascularization and activation of dural α-SMA+ fibroblasts, resulting in rare focal fibrotic lesions. Notably, hematopoietic aggregates containing MKs and Mφ accumulated within the dura mater in MPN mice, indicating focal extramedullary hematopoiesis.

MPNs induce extensive but compartment-specific remodeling across the skull-brain axis. Whereas cranial BM develops a predominantly profibrotic state associated with altered bone homeostasis, the adjacent dura mater exhibits marked inflammatory, vascular, and fibrotic remodeling. Importantly, similar alteration were evident in the brain, where MPN mice exhibited increased immune cell infiltration, elevated inflammatory cytokines, and reduced microglial counts. Consistent with this, MPN patients demonstrated a pan-hypometabolic brain state on 18F-FDG PET/CT, while UK Biobank analyses identified significant thalamic microstructural alterations. Together, these findings identify the skull-brain axis as a previously unrecognized site of MPN pathology and establish a mechanistic link between cranial hematopoietic remodeling, neuroimmune dysfunction, and neurological manifestations in MPN.

Tesa Klenovšek, MS: No relevant conflicts of interest to declare.